These Analysts Revise Their Forecasts On Harrow Following Q4 Results

Core Viewpoint - Harrow Inc. reported mixed financial results for the fourth quarter, with earnings per share falling short of expectations while sales exceeded consensus estimates [1][2]. Financial Performance - Fourth quarter earnings were reported at 17 cents per share, missing the consensus estimate of 38 cents [1]. - Sales increased from $66.81 million to $89.09 million, surpassing the consensus estimate of $88.45 million [1]. Research and Development Expenses - Harrow incurred $8.5 million in acquired in-process research and development expenses due to the acquisition of Melt Pharmaceuticals during the fourth quarter and full-year ended December 31, 2025 [2]. Future Sales Expectations - The company anticipates fiscal 2026 sales to be between $350 million and $365 million, which is below the consensus estimate of $386.26 million [2]. Stock Performance - Following the earnings announcement, Harrow shares rose by 3% to $39.76 in pre-market trading [2]. Analyst Ratings and Price Targets - HC Wainwright & Co. analyst Yi Chen maintained a Buy rating on Harrow and raised the price target from $69 to $70 [3]. - Cantor Fitzgerald analyst Steve Seedhouse maintained an Overweight rating but lowered the price target from $94 to $91 [3].